Tissue Regenix Group plc – Founder recognised at the Women of Outstanding Achievement Awards

10 May 2011

Tissue Regenix, the regenerative medical device company, is pleased to note that Professor Eileen Ingham, Board member and academic founder of the company, has been recognised for her achievements in scientific research at the UKRC's (UK Research Council) Women of Outstanding Achievement Awards.

Professor Ingham received the top award for Innovation and Entrepreneurship in Academia and Research, sponsored by the Science and Technology Facilities Council (STFC), at a ceremony held at the Royal Academy of Engineering in London.

Professor Ingham is a Professor of Medical Immunology and director of the Institute of Medical and Biological Engineering at Leeds University, where she has helped to establish a world leading centre of excellence in medical engineering with over 100 academic researchers, and with current external grant income in excess of £50m.

Professor Ingham will present an overview of Tissue Regenix's dCELL® technology and the company's research pipeline at an R&D update meeting entitled "Exploring the potential of Tissue Regenix's regenerative technology platform across multiple therapeutic areas", on Wednesday, 11 May at the offices of Financial Dynamics, Holborn Gate, 26 Southampton Buildings, London WC2A 1PB.

Professor Ingham said, "I'm surprised and delighted to have been presented with this award. It's a privilege to be able to spend my working life in activities that I truly enjoy – and then be recognised for my work. During my career I have been supported by a number of entrepreneurial mentors and have worked with many outstanding scientists, engineers and clinicians. I hope that my work can be an inspiration to others too."


Financial Dynamics
Ben Atwell / John Dineen
+44 (0) 20 7831 3113

Tissue Regenix Group plc
Antony Odell
+44 (0) 1904 567 609

About Tissue Regenix

Tissue Regenix, the RegenMed Company, was incorporated in May 2006 to commercialise the academic research of Professor Eileen Ingham and Professor John Fisher from the University of Leeds in the field of tissue decellularisation. Its dCELL® Technology comprises a patented process which removes cells and other components from human and animal tissue allowing it to be used without anti-rejection drugs to replace worn out or diseased body parts.

About dCELL® Technology

The process comprised within the dCELL® Technology involves the production of biological scaffolds created by taking a piece of human or animal tissue that is equivalent to the diseased or damaged body part which is being replaced, treating such tissue with a series of gentle chemical washes and then sterilising it. The end product is a scaffold which can be stored under normal conditions at room temperature like any synthetic medical device and, when it is implanted into the body, it repopulates with the patient's own cells using natural biological repair mechanisms. Tissue Regenix's strategy is to continue to use its core dCELL® Technology as a platform to develop a range of products using the established medical device regulatory pathway to deliver solutions to unmet clinical needs. The three priority markets for the application of the technology are: Vascular (e.g. Vascular Patches); Cardiac (e.g. Heart Valves); and Orthopaedics (e.g. Meniscus).